| View |
|
BR-1394
|
Trastuzumab
|
Trazimera
|
150 mg
|
Powder For Concentrate For Solution For Infusion (IV)
|
Monoclonal Antibodies [HER2 (Human Edpidermal Growth Factor Receptor 2) Inhibitors)
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
Initial
|
30 March 2022
|
30 March 2027
|
| View |
|
BR-1395
|
Trastuzumab
|
Trazimera
|
440 mg
|
Powder For Concentrate For Solution For Infusion (IV)
|
Monoclonal Antibodies [HER2 (Human Edpidermal Growth Factor Receptor 2) Inhibitors)
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
Initial
|
30 March 2022
|
30 March 2027
|
| View |
|
BR-1396
|
Polatuzumab vedotin
|
Polivy
|
140 mg
|
Powder for Concentrate for Solution for
Infusion (IV)
|
-
|
BSP Pharmaceuticals S.p.A.
|
Italy
|
Monitored Release
|
01 April 2022
|
01 April 2027
|
| View |
BR-1397_PI_01.pdf
|
BR-1397
|
Brolucizumab
|
Vsiqq
|
120 mg/mL (27.6 mg/0.23 mL)
|
Solution for Injection (Intravitreal)
|
Antineovascularization Agent
|
Novartis Pharma Stein AG Technical Operations
|
Switzerland
|
Monitored Release (MR)
|
01 April 2022
|
01 April 2027
|
| View |
BR-1398_PI_01.pdf
|
BR-1398
|
Secukinumab
|
Cosentyx
|
300 mg/ 2 mL
|
Solution For Injection (SC)
|
Interleukin Inhibitors
|
Novartis Pharma Stein AG, Pharmaceutical
Operations Schweiz Steriles
|
Switzerland
|
Initial
|
13 April 2022
|
13 April 2027
|
| View |
|
BR-1399
|
Secukinumab
|
Cosentyx
|
300 mg/ 2 mL
|
Solution For Injection (SC)
|
Interleukin Inhibitors
|
Novartis Pharma Stein AG, Pharmaceutical
Operations Schweiz Steriles
|
Switzerland
|
Initial
|
13 April 2022
|
13 April 2027
|
| View |
|
BR-1400
|
Trastuzumab
|
Trazimera
|
440 mg
|
Powder for Concentrate for Solution for Infusion (IV)
|
Monoclonal Antibodies
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
Initial
|
21 April 2022
|
21 April 2027
|
| View |
|
BR-1401
|
Trastuzumab
|
Kanjinti
|
150 mg
|
Powder For Concentrate For Solution For Infusion (IV)
|
-
|
Amgen Technology (Ireland) Unlimited Company
|
Ireland
|
Initial
|
20 May 2022
|
20 May 2027
|
| View |
BR-1402_PI_01.pdf
|
BR-1402
|
Bevacizumab
|
Abevmy
|
400 mg / 16 mL (25 mg/mL)
|
Vascular Endothelial Growth Factor Inhibitors
|
Vascular Endothelial Growth Factor Inhibitors
|
Biocon Limited
|
India
|
Initial (Reconstruction)
|
15 March 2023
|
23 May 2027
|
| View |
BR-1403_PI_01.pdf
|
BR-1403
|
Bevacizumab
|
Abevmy
|
100 mg / 4mL (25 mg/mL)
|
Concentrate For Solution Fo Infusion (IV)
|
Vascular Endothelial Growth Factor Inhibitors
|
Biocon Limited
|
India
|
Initial (Reconstruction)
|
14 March 2023
|
23 May 2027
|
| View |
|
BR-1404
|
Rituximab
|
Ruxience
|
10mg/mL
|
Concentrate for Solution for Infusion (IV)
|
Monoclonal Antibodies
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
Initial
|
30 May 2022
|
30 May 2027
|
| View |
|
BR-1405
|
Rituximab
|
Redditux
|
10mg/mL
|
Concentrate For Solution For Infusion (IV)
|
-
|
Dr. Reddy's Laboratories Ltd.
|
India
|
Initial
|
21 June 2022
|
21 June 2027
|
| View |
|
BR-1406
|
Insulin Aspart
|
Fiasp
|
100 Units (equivalent to 3.5 mg)/mL
|
Solution for
Injection (IV/SC)
|
Antidiabetics
|
Novo Nordisk Pharmaceutical Industries, LP
|
United States of America
|
Initial
|
14 July 2022
|
14 July 2027
|
| View |
|
BR-1407
|
Pertuzumab + Trastuzumab
|
Phesgo
|
1200 mg / 600 mg/ 15 mL
|
Solution For Injection (SC)
|
-
|
F. Hoffmann-La Roche, Ltd.
|
Switzerland
|
Monitored Release
|
29 July 2022
|
29 July 2027
|
| View |
|
BR-1408
|
Pertuzumab + Trastuzumab
|
Phesgo
|
600 mg / 600 mg/ 10mL
|
Solution For Injection (SC)
|
-
|
F. Hoffmann-La Roche, Ltd.
|
Switzerland
|
Monitored Release
|
29 July 2022
|
29 July 2027
|
| View |
|
BR-1409
|
Epoetin Alfa
|
Erysaa
|
4,000 IU/0.4 mL
|
Solution for Injection (IV)
|
-
|
PanGen Biotech Inc.
|
Korea
|
Initial
|
16 August 2022
|
16 August 2027
|
| View |
|
BR-1410
|
Sulodexide
|
Angioflux
|
250 LSU
|
Softgel Capsule
|
-
|
Catalent Italy S.P.A.
|
Italy
|
Automatic Renewal (Reconstruction)
|
23 August 2022
|
28 December 2025
|
| View |
BR-1411_PI_01.pdf
|
BR-1411
|
Semaglutide
|
Rybelsus
|
7 mg
|
Tablet
|
Glucagon-like Peptide-1 (GLP-1) Analogue
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release
|
18 August 2022
|
18 August 2027
|
| View |
BR-1412_PI_01.pdf
|
BR-1412
|
Semaglutide
|
Rybelsus
|
14 mg
|
Tablet
|
Glucagon-like Peptide-1 (GLP-1) Analogue
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release
|
18 August 2022
|
18 August 2027
|
| View |
BR-1413_PI_01.pdf
|
BR-1413
|
Semaglutide
|
Rybelsus
|
3 mg
|
Tablet
|
Glucagon-like Peptide-1 (GLP-1) Analogue
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release
|
18 August 2022
|
18 August 2027
|